Aurora Cannabis has acquired Internode Pharma Limited and HAP Pharma Limited, two licensed UK companies involved in importing, wholesaling, and pharmacy services. This acquisition gives Aurora direct control over the UK supply chain, enabling it to better serve the growing medical cannabis market in the UK, which has about 70 million people. The move is expected to improve operational efficiency, reduce reliance on third parties, and increase Aurora's market share and adjusted EBITDA in future quarters. Aurora plans to further invest in expanding its UK distribution capacity to meet rising patient demand.
Aurora Cannabis has responded to Curaleaf's unsolicited hostile takeover bid by disputing Curaleaf's claims about Aurora's business performance and growth. Aurora highlights its 17% year-over-year international revenue growth, especially in Germany a...
Tilray Brands' stock rose 6% following the U.S. Treasury's announcement to double buybacks of long-term government debt, which lowered yields and boosted speculative stocks. Despite this gain, Tilray remains down 48% year to date, underperforming its...
